| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Ganguli, J S Bra. The effects of risperidone and olanzapine on the indications for clozapine. Psychopharmacology bulletin. vol 34. issue 1. 1998-05-21. PMID:9564203. |
the effects of the availability of risperidone and olanzapine on the indications for which clozapine is prescribed (treatment-resistance, treatment-intolerance, and/or negative symptoms) were examined for 252 patients with schizophrenia who began treatment at our hospital between june 1990 and june 1997. |
1998-05-21 |
2023-08-12 |
Not clear |
| N C Beck, S R Greenfield, H Gotham, A A Menditto, P Stuve, C A Hemm. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. The journal of the American Academy of Psychiatry and the Law. vol 25. issue 4. 1998-05-14. PMID:9460034. |
this study examines the effectiveness of risperidone compared with traditional neuroleptic medications in the areas of clinical functioning and aggressive behaviors in a sample of inpatients diagnosed with chronic schizophrenia. |
1998-05-14 |
2023-08-12 |
human |
| J L Waddington, P J Scully, E O'Callagha. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophrenia research. vol 28. issue 2-3. 1998-05-14. PMID:9468355. |
this article first evaluates the significance of clozapine and risperidone; it then reviews some of the new antipsychotics and how they might be classified vis-a-vis potential advantages for patients, outlines putative mechanisms and new therapeutic targets, and considers whether such agents may act on any disease process inherent to schizophrenia. |
1998-05-14 |
2023-08-12 |
Not clear |
| A Davies, M A Adena, N A Keks, S V Catts, T Lambert, I Schweitze. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clinical therapeutics. vol 20. issue 1. 1998-04-30. PMID:9522104. |
comparative clinical trials have shown that the novel antipsychotic agent risperidone tends to have greater efficacy (i.e., clinical response defined as a > or = 20% reduction in total scores on the positive and negative syndrome scale) than haloperidol in patients with chronic schizophrenia and poses less risk of extrapyramidal symptoms (eps). |
1998-04-30 |
2023-08-12 |
Not clear |
| A Davies, M A Adena, N A Keks, S V Catts, T Lambert, I Schweitze. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clinical therapeutics. vol 20. issue 1. 1998-04-30. PMID:9522104. |
we used dersimonian and laird's random-effects model to analyze pooled patient data from available randomized, double-masked, comparative trials of risperidone and haloperidol in patients with schizophrenia treated for at least 4 weeks at recommended doses. |
1998-04-30 |
2023-08-12 |
Not clear |
| A Davies, P C Langley, N A Keks, S V Catts, T Lambert, I Schweitze. Risperidone versus haloperidol: II. Cost-effectiveness. Clinical therapeutics. vol 20. issue 1. 1998-04-30. PMID:9522115. |
we used guidelines issued by the australian pharmaceutical benefits advisory committee to construct a model for comparing the cost-effectiveness of risperidone and haloperidol over a 2-year period in patients with chronic schizophrenia. |
1998-04-30 |
2023-08-12 |
Not clear |
| G Bondolfi, H Dufour, M Patris, J P May, U Billeter, C B Eap, P Bauman. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. The American journal of psychiatry. vol 155. issue 4. 1998-04-22. PMID:9545995. |
risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. |
1998-04-22 |
2023-08-12 |
Not clear |
| H J Möller, J Bäuml, F Ferrero, J Fuger, C Geretsegger, S Kasper, W Kissling, H Schuber. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. European archives of psychiatry and clinical neuroscience. vol 247. issue 6. 1998-04-09. PMID:9477007. |
risperidone in the treatment of schizophrenia: results of a study of patients from germany, austria, and switzerland. |
1998-04-09 |
2023-08-12 |
Not clear |
| H J Möller, J Bäuml, F Ferrero, J Fuger, C Geretsegger, S Kasper, W Kissling, H Schuber. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. European archives of psychiatry and clinical neuroscience. vol 247. issue 6. 1998-04-09. PMID:9477007. |
patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks. |
1998-04-09 |
2023-08-12 |
Not clear |
| R Perry, C Pataki, D M Munoz-Silva, J Armenteros, R R Silv. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. Journal of child and adolescent psychopharmacology. vol 7. issue 3. 1998-03-24. PMID:9466234. |
the rationale for trying risperidone in this population includes its dopamine-blocking activity; its seemingly lower incidence of tardive dyskinesia when compared to standard neuroleptics; the possibility that risperidone may ameliorate the social withdrawal of pdd, as it does the negative symptoms in schizophrenia; and substantial effects on serotonergic neurotransmission, which has been shown to be dysregulated in some patients with pdd. |
1998-03-24 |
2023-08-12 |
human |
| J Addington, D Addingto. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 42. issue 9. 1998-02-27. PMID:9429073. |
neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol. |
1998-02-27 |
2023-08-12 |
Not clear |
| G Mercer, A Finlayson, E C Johnstone, C Murray, D G Owen. A study of enhanced management in patients with treatment-resistant schizophrenia. Journal of psychopharmacology (Oxford, England). vol 11. issue 4. 1998-02-25. PMID:9443524. |
the clinical efficacy of two intensive treatment packages (one including the new antipsychotic risperidone and the other not doing so) was compared with that of standard management in 43 patients with long-standing treatment-resistant schizophrenia. |
1998-02-25 |
2023-08-12 |
Not clear |
| D L Fogelson, H Sternbach, D Payn. A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. Journal of clinical psychopharmacology. vol 17. issue 6. 1998-02-06. PMID:9408817. |
a naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. |
1998-02-06 |
2023-08-12 |
Not clear |
| S R Marder, J M Davis, G Chouinar. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. The Journal of clinical psychiatry. vol 58. issue 12. 1998-02-04. PMID:9448657. |
the effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the north american trials. |
1998-02-04 |
2023-08-12 |
Not clear |
| S R Marder, J M Davis, G Chouinar. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. The Journal of clinical psychiatry. vol 58. issue 12. 1998-02-04. PMID:9448657. |
in two double-blind trials conducted in north america, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo. |
1998-02-04 |
2023-08-12 |
Not clear |
| G Mas. Atypical neuroleptics in the treatment of early onset schizophrenia. Panminerva medica. vol 39. issue 3. 1998-01-13. PMID:9360425. |
the aim of this critical review is to describe clinical use of atypical neuroleptics clozapine and risperidone in children and adolescents with early-onset schizophrenia. |
1998-01-13 |
2023-08-12 |
Not clear |
| [3 years of clinical experience with risperidone: new therapeutic standards in the management of schizophrenia]. Der Nervenarzt. vol 67. issue 10 Suppl Neue Thera. 1997-12-30. PMID:9403092. |
[3 years of clinical experience with risperidone: new therapeutic standards in the management of schizophrenia]. |
1997-12-30 |
2023-08-12 |
Not clear |
| R R Conley, R W Buchana. Evaluation of treatment-resistant schizophrenia. Schizophrenia bulletin. vol 23. issue 4. 1997-12-16. PMID:9366002. |
a systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of clozapine, risperidone, and olanzapine. |
1997-12-16 |
2023-08-12 |
Not clear |
| R Gutierrez-Esteinou, J A Greb. Risperidone: an analysis of the first three years in general use. International clinical psychopharmacology. vol 12 Suppl 4. 1997-12-10. PMID:9352340. |
further studies have confirmed the efficacy of risperidone across a broad range of patients with schizophrenia who were not represented in the two pivotal clinical trials. |
1997-12-10 |
2023-08-12 |
Not clear |
| R Gutierrez-Esteinou, J A Greb. Risperidone: an analysis of the first three years in general use. International clinical psychopharmacology. vol 12 Suppl 4. 1997-12-10. PMID:9352340. |
two studies confirm the efficacy of risperidone in first-episode schizophrenia and subanalyses of these studies suggest that the dose in these patients should be lower than in patients with chronic schizophrenia. |
1997-12-10 |
2023-08-12 |
Not clear |